First Department of Internal Medicine, Division of Respiratory Medicine, Infectious Disease and Allergology, Kansai Medical University, Japan.
Department of Emergency Medicine, Kansai Medical University Medical Center, Japan.
J Infect Chemother. 2022 Jul;28(7):902-906. doi: 10.1016/j.jiac.2022.03.010. Epub 2022 Mar 19.
The objective of this study was to clarify the clinical differences between nursing and healthcare-associated pneumonia (NHCAP) and community-acquired pneumonia (CAP) due to COVID-19. We also investigated the clinical characteristics to determine whether there is a difference between the variant and non-variant strain in patients with NHCAP due to COVID-19. In addition, we analyzed the clinical outcomes in NHCAP patients with mental disorders who were hospitalized in a medical institution for treatment of mental illness.
This study was conducted at five institutions and assessed a total of 836 patients with COVID-19 pneumonia (154 cases were classified as NHCAP and 335 had lineage B.1.1.7.).
No differences in patient background, clinical findings, disease severity, or outcomes were observed in patients with NHCAP between the non-B.1.1.7 group and B.1.1.7 group. The median age, frequency of comorbid illness, rates of intensive care unit stay, and mortality rate were significantly higher in patients with NHCAP than in those with CAP. Among the patients with NHCAP, the mortality rate was highest at 37.5% in patients with recent cancer treatment, followed by elderly or disabled patients receiving nursing care (24.3%), residents of care facilities (23.0%), patients receiving dialysis (13.6%), and patients in mental hospitals (9.4%).
Our results demonstrated that there were many differences in the clinical characteristics between NHCAP patients and CAP patients due to COVID-19. It is necessary to consider the prevention and treatment content depending on the presence or absence of applicable criteria for NHCAP.
本研究旨在阐明 COVID-19 导致的护理相关性肺炎(NHCAP)和社区获得性肺炎(CAP)之间的临床差异。我们还调查了临床特征,以确定 COVID-19 导致的 NHCAP 患者中变异株和非变异株之间是否存在差异。此外,我们分析了在医疗机构住院治疗精神疾病的精神障碍 NHCAP 患者的临床结局。
本研究在五家机构进行,共评估了 836 例 COVID-19 肺炎患者(154 例为 NHCAP,335 例为 B.1.1.7 谱系)。
在非 B.1.1.7 组和 B.1.1.7 组的 NHCAP 患者中,患者背景、临床发现、疾病严重程度或结局均无差异。NHCAP 患者的中位年龄、合并症频率、入住重症监护病房率和死亡率均显著高于 CAP 患者。在 NHCAP 患者中,近期接受癌症治疗的患者死亡率最高(37.5%),其次是接受护理的老年或残疾患者(24.3%)、护理机构居民(23.0%)、接受透析的患者(13.6%)和精神医院患者(9.4%)。
我们的结果表明,COVID-19 导致的 NHCAP 患者与 CAP 患者的临床特征存在许多差异。需要根据是否存在 NHCAP 的适用标准来考虑预防和治疗内容。